Considering Peter French's interview, any thoughts on whether that Q4 efficacy data will get pushed till early next year since patient 8 seems to not yet been dosed? Is there a possibility of announcing some data at the liver meeting or AGM? Is it possible that if they dose another patient soon, and they do have a viral reduction, would they even include that? Would it make sense not to since SVR is technically considered 6 months after treatment, and may not even be reached with this current cohort. Or could they announce at least a viral load reduction as a positive sign but not declare SVR necessarily?
Just thinking out loud peeps.
Thoughts?
BLT Price at posting:
43.5¢ Sentiment: Buy Disclosure: Held
